Stock STSA SATSUMA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Satsuma Pharmaceuticals, Inc.

Equities

STSA

US80405P1075

Biotechnology & Medical Research

Business Summary

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a therapeutic product for the acute treatment of migraine. The Company's product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate (DHE), which is designed to self-administered with a pre-filled, single-use, nasal delivery device. STS101 also incorporates an improved 2nd-generation nasal delivery device. STS101 is specifically designed to deliver the clinical advantages of DHE while overcoming its shortcomings.

Number of employees: 25

Managers

Managers TitleAgeSince
Ryoichi Nagata CEO
 Chief Executive Officer 65 23-06-07
Mic Iwashima COO
 Chief Operating Officer 46 16-12-31
Detlef F. Albrecht CTO
 Chief Tech/Sci/R&D Officer 63 17-06-30
Shannon Strom LAW
 General Counsel 48 18-04-30
Robert M. Janosky PRN
 Corporate Officer/Principal - 20-03-04
Robert Schultz PRN
 Corporate Officer/Principal 60 17-06-30
Shinji Nitanda SEC
 Corporate Secretary 55 23-06-07

Members of the board

Members of the board TitleAgeSince
Ryoichi Nagata CEO
 Chief Executive Officer 65 23-06-07
Shuichi Kanazashi BRD
 Director/Board Member 64 23-06-07
Ken Takanashi BRD
 Director/Board Member 59 16-05-31
Shunji Haruta BRD
 Director/Board Member - 23-06-07
Akihisa Mori BRD
 Director/Board Member - 23-06-07

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 33,152,498 27,782,705 ( 83.80 %) 0 83.80 %

Company contact information

Satsuma Pharmaceuticals, Inc.

4819 Emperor Boulevard Suite 340

27703, Durham

+650 410 3200

http://www.satsumarx.com
address Satsuma Pharmaceuticals, Inc.(STSA)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.63% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.62% 96.29B
ARGENX SE Stock argenx SE
+2.56% 22.18B
BIONTECH SE Stock BioNTech SE
-16.67% 21.2B
GENMAB A/S Stock Genmab A/S
-9.07% 18.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.74% 17.38B
BEIGENE, LTD. Stock BeiGene, Ltd.
-13.21% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.41% 13.97B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.57% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. STSA Stock
  4. Company Satsuma Pharmaceuticals, Inc.